PF-4523655

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NamePF-4523655
Drug Alias NamePF-04523655PFE-4523655REDD-14-NPPF-4523655RTP-801i-14 +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionDNA damage-inducible transcript 4 protein inhibitorsRNA interference
TargetsDNA damage-inducible transcript 4 protein
Therapy Area/IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[18] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSilence Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncQuark Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[5] 

Other Information

ATC CodeN/A
Related LinksN/A